Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Chem ; 274(45): 32469-77, 1999 Nov 05.
Article in English | MEDLINE | ID: mdl-10542292

ABSTRACT

One class of zinc metalloproteases, represented by neutral endopeptidase 24.11 and endothelin-converting enzyme, has been shown to be involved in proteolytic activation or inactivation of many regulatory peptides. Here, we report molecular cloning and characterization of a novel member of this type II membrane-bound metalloprotease family, termed soluble secreted endopeptidase (SEP). Alternative splicing results in the generation of another transcript, SEP(Delta), which lacks a 69-base pair nucleotide segment following the transmembrane helix. Both SEP and SEP(Delta) mRNA are detected in all mouse tissues examined. Transfection of an SEP cDNA expression construct resulted in the expression of the membrane-bound form of SEP in the early secretory pathway as well as the soluble secreted form of the enzyme in the culture medium. In contrast, transfection of the SEP(Delta) cDNA only results in the expression of the membrane-bound form. In vitro enzymological analysis of the recombinant soluble form of SEP demonstrated that it hydrolyzes a variety of vasoactive peptides, including endothelin-1, atrial natriuretic peptide, and angiotensin I. This activity of SEP was inhibited by phosphoramidon and the neutral endopeptidase 24.11 specific inhibitor thiorphan, but it was only partially inhibited by the endothelin-converting enzyme specific inhibitor FR901533. These findings suggest that SEP is a novel metalloprotease that possesses a broad substrate specificity and that it may be involved in the metabolism of biologically active peptides intracellulary as well as extracellularly.


Subject(s)
Angiotensin I/metabolism , Atrial Natriuretic Factor/metabolism , Endothelin-1/metabolism , Metalloendopeptidases/isolation & purification , Metalloendopeptidases/metabolism , Alternative Splicing , Amino Acid Sequence , Animals , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/physiology , Base Sequence , CHO Cells , Cricetinae , DNA, Complementary/chemistry , Endothelin-Converting Enzymes , Enzyme Inhibitors/pharmacology , Humans , Hydrolysis , Metalloendopeptidases/genetics , Mice , Molecular Sequence Data , Solubility , Tetracyclines/pharmacology , Transfection
2.
J Biol Chem ; 274(3): 1509-18, 1999 Jan 15.
Article in English | MEDLINE | ID: mdl-9880527

ABSTRACT

Endothelin-converting enzyme-1 (ECE-1) is a type II membrane protein that catalyzes the proteolytic activation of big endothelin-1 to endothelin-1 (ET-1). The subcellular distribution of ECE-1, and hence the exact site of physiological activation of big ET-1, remains controversial. Here, we demonstrate with several complementary methods that the two alternatively spliced bovine ECE-1 isoforms, ECE-1a and ECE-1b, differing only in the first 30 amino acids of their N-terminal cytoplasmic tails, exhibit strikingly distinct intracellular sorting patterns. Bovine ECE-1a, which is responsible for the intracellular cleavage of big ET-1 in endothelial cells, is constitutively recruited into the lysosome, where it is rapidly degraded. In contrast, bovine ECE-1b, the isoform found in cultured smooth muscle cells, is transported to the plasma membrane by a default pathway and functions as an ectoenzyme. Mutational analyses reveal that the N-terminal tip of the cytoplasmic domain of bovine ECE-1a contains novel proline-containing signals that mediate constitutive lysosomal targeting. Analyses of chimeric ECE-1/transferrin receptors demonstrate that the cytoplasmic tail of bovine ECE-1a is sufficient for the lysosomal delivery and rapid degradation. Our results suggest that the distinct intracellular targeting of bovine ECE-1 isoforms may provide new insights into functional aspect of the endothelin system and that the cell permeability of ECE inhibitor compounds should be carefully considered during their pharmacological development.


Subject(s)
Alternative Splicing , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Lysosomes/metabolism , Metalloendopeptidases/metabolism , Protein Sorting Signals/genetics , Protein Sorting Signals/metabolism , Amino Acid Sequence , Animals , CHO Cells , Cattle , Cricetinae , Cytoplasm/metabolism , DNA Mutational Analysis , Endothelin-1/metabolism , Endothelin-Converting Enzymes , Molecular Sequence Data , Muscle, Smooth/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...